Results from pivotal trial showed treatment with SAGE-217 resulted in rapid, clinically meaningful improvement in major depressive disorder (MDD) symptoms across multiple measures and time points SAGE-217 is currently being investigated in the Phase 3 MOUNTAIN trial for the treatment of MDD, with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the

ZULRESSO™ (brexanolone) injection CIV, the first treatment specifically indicated for postpartum depression, commercially launched in the U.S. in late-June, with first patients treated in July 2019 Commercial execution is progressing as expected and on-track across key focus areas including

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on August 1, 2019 , the

Data from Phase 2 open-label study of SAGE-217 in bipolar depression demonstrate rapid improvement compared to baseline; analysis of datasets from previously completed studies reveal encouraging findings relevant to the development of SAGE-217 in treatment-resistant depression and generalized

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 11, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host a live webcast on Tuesday, August 6, 2019 at 8:00 a.m.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 3, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 1, 2019 , the Compensation Committee of Sage’s Board of

Event will provide an R&D and portfolio review across the depression, neurology and neuropsychiatric franchises CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 27, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the BMO Prescriptions for Success Healthcare